Seminars in Hematology
Volume 44, Issue 3 , Pages 133-137 , July 2007

Hematopoietic Growth Factors for the Treatment of Inherited Cytopenias

  • Cornelia Zeidler
    • ,
  • Karl Welte

      Affiliations

    • Corresponding Author InformationAddress correspondence to Karl Welte, MD, PhD, Department for Pediatric Hematology/Oncology, Kinderklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str 1, 30625 Hannover, Germany.

References 

  1. Carnot P, Deflandre C. Sur l’activité hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci. 1906;143:432–435
  2. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haematopoietic cells. Nature. 1989;339:27–30
  3. Kostmann R. Infantile genetic agranulocytosis. Acta Pediatr Scand. 1956;45:1–78
  4. Kostmann R. Infantile genetic agranulocytosis: A review with presentation of ten new cases. Acta Pediatr Scand. 1975;64:362–368
  5. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39:86–92
  6. Aprikyan AA, Liles WC, Boxer LA, Dale DC. Mutant elastase in pathogenesis of cyclic and severe congenital neutropenia. J Pediatr Hematol Oncol. 2002;24:784–786
  7. Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, et al Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96:2317–2322
  8. Horwitz M, Benson KF, Person RE, Aprikyan AG, Dale DC. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoesis. Nat Genet. 1999;23:433–436
  9. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, Battmer K, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med. 2006;12:1191–1197
  10. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol. 2006;43:189–195
  11. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene for the granulocyte-colony stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487–493
  12. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood. 2007;109:93–99
  13. Rappeport J, Parkman R, Newburger P, Camitta BM, Chusid MJ. Correction of infantile granulocytosis (Kostmann syndrome) by allogeneic bone marrow transplantation. Am J Med. 1980;68:605–609
  14. Souza L, Boone T, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232:61–65
  15. Bonilla M, Gillio A, Ruggeiro M, Kernan NA, Brochstein JA, Abboud M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989;320:1574–1580
  16. Bonilla M, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congential neutropenias. Br J Hematol. 1994;88:723–730
  17. Donadieu J, Leblanc T, Meunier BB, Barkaoui M, Fenneteau O, Bertrand Y, et al. Analysis of risk factors for myelodysplasia/leukemia and infectious death among patients with congenital neutropenia: Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45–53
  18. Dale D, Bonilla M, Davis M, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81:2496–2502
  19. Zeidler C, Boxer L, Dale DC, Freedman MH, Kinsey S, Welte K. Management of Kostmann syndrome in the G-CSF era. Br J Haematol. 2000;109:490–495
  20. Welte K, Zeidler C, Reiter A, Muller W, Odenwald E, Souza L, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood. 1990;75:1056–1063
  21. Zeidler C, Vogel R, Wyres M, Welte K. Beneficial effects of stem cell factor (SCF) in children with severe congenital neutropenias refractory to G-CSF. Blood. 1998;92:380a;(abstr)
  22. Zeidler C, Welte K, Barak Y, Barriga F, Bolyard AA, Boxer L, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000;95:1195–1198
  23. Gilman P, Jackson D, Guild H. Congenital agranulocytosis: Prolonged survival and terminal acute leukemia. Blood. 1970;36:576–585
  24. Rosen R, Kang S. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr. 1979;94:406–408
  25. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2005;107:4628–4635
  26. Winearls CH, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175
  27. Das REG, Milne A, Rowley M, Smith ECG, Cotes PM. Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi’s anemias. Br J Haematol. 1992;82:601
  28. Hammond D, Keighley G. The erythrocyte-stimulating factor in serum and urine in congenital hypoplastic anemia. Am J Dis Child. 1960;100:466
  29. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21:169–175
  30. Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006;79:1110–1118
  31. Niemeyer CM, Baumgarten E, Holldack J, Meier I, Trenn G, Jobke A, et al. Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol. 1991;88:276–280
  32. Dunbar CE, Smith DA, Kimball J, Garrison J, Nienhues AW, Young NS. Treatment of Diamond-Blasckfan anemia with hematopoiesis growth factors, granulocyte-macrophage colony-stimulating factor and interleukin-3: Sustained remission following IL-3. Br J Haematol. 1991;79:316–321
  33. Gillio AP, Faulkner LB, Alter BP, Reilly L, Klafter R, Heller G, et al. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood. 1993;82:744–751
  34. Olivieri F, Feig SA, Valentino L, Berriman AM, Shore R, Freedman MH. Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood. 1994;83:2444–2450
  35. Tamary H, Shalev H, Pinsk V, Zoldan M, Zaizov R. No response to recombinant human erythropoietin therapy in patients with congenital dyserythropoietic anemia type I. Pediatr Hematol Oncol. 1999;16:165–168
  36. Heimpel H, Schwarz K, Ebnöther M, Goede JS, Heydrich D, Kamp T, et al. Congenital dyserythropoietic anemia type I (CDA I): Molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood. 2006;107:334–340
  37. Geddis AE. Inherited thrombocytopenia: Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Semin Hematol. 2006;43:196–203
  38. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: A retrospective clinical analysis of 20 patients. Br J Haematol. 2005;131:636–644
  39. Germeshausen M, Ballmaier M, Welte K. c-mpl mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mut. 2006;27:296
  40. Wang Z, Skokowa J, Pramono A, Ballmaier M, Welte K. Thrombopoietin regulates differentiation of Rhesus monkey embryonic stem cells to hematopoietic cells. Ann N Y Acad Sci. 2005;1044:29–40
  41. Kutler DI, Singh B, Satagopan J. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249–1256
  42. Guinan EC, Lopez KD, Huhn RD, Felser JM, Nathan DG. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr. 1994;124:144–150
  43. Rackoff WR, Orazi A, Robinson CA, Cooper RJ, Alter BP, Freedman MH, et al. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: A pilot study. Blood. 1996;88:1588–1593
  44. Scagni P, Saracco P, Timeus F, Farinasso L, Dall’Aglio M, Bosa EM, et al. Use of recombinant granulocyte colony-stimulating factor in Fanconi’s anemia. Haematologica. 1998;83:432–437
  45. Croop JM, Cooper R, Fernandez C, Graves V, Kreissman S, Hanenberg H, et al. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood. 2001;98:2917–2921
  46. Si Y, Ciccone S, Yang FC, Yuan J, Zeng D, Chen S, et al. Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/-and Fancg-/- mice. Blood. 2006;108:4283–4287

PII: S0037-1963(07)00066-2

doi: 10.1053/j.seminhematol.2007.04.003

Seminars in Hematology
Volume 44, Issue 3 , Pages 133-137 , July 2007

Article Tools

* Image Usage & Resolution